|22 October 2019
The VALIDATE Network's pump-priming grants, worth up to £50,000, aim to accelerate Vaccine Research and Development for complex intracellular pathogens significant to LMICs. Projects can last up to 12 months, with an initial focus on Mycobacterium tuberculosis, Leishmania spp, Burkholderia pseudomallei, and Mycobacterium leprae.
|07 November 2019
The European and Developing Countries Clinical Trials Partnership are offering awards to partnerships looking to conduct clinical trials which will help develop new or improved medical products (drugs and vaccinations) against antibiotic resistant pathogens from the World Health Organisation's priority list; specifically Campylobacter, Salmonella, Streptococcus pneumoniae, and Mycobacterium Tuberculosis. Various eligibility rules apply, and proposals must include at least one clinical trial (phase I to IV) in sub-saharan Africa.